Business Wire

PUMA and Modibodi ® Present Range of Period Underwear for Women

1.3.2022 10:00:00 CET | Business Wire | Press Release

Share

Sports company PUMA and global leak-proof apparel company Modibodi® have teamed up to launch a range of leak-free period underwear and activewear, created to help women stay comfortable and active during their period whilst making a positive environmental impact.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220301005090/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sports company PUMA and global leak-proof apparel company Modibodi® have teamed up to launch a range of leak-free period underwear and activewear, created to help women stay comfortable and active during their period whilst making a positive environmental impact. (Photo: Business Wire)

PUMA together with Modibodi believes that everybody who wants to participate in exercise or sport should be given the opportunity to stay active and play, fueling the motivation behind PUMA x Modibodi’s exclusive global partnership under the “She Moves Us” platform.

“Even in the 21st century, periods and leaks still prevent women from participating in sports. Studies have revealed that girls’ participation in sport drops from 69% (ages 11-12) to 45% (ages 13-15)*. Additionally, the single-use plastic from disposable products can continue to pollute the environment for hundreds of years,” said Erin Longin, Global Director Run/Train at PUMA. “As a global brand, we felt it important to do our part to address this issue. The PUMA x Modibodi collaboration allows women to stay active, without having to worry about leaks, while reducing their monthly waste from period products.”

Disposable products pollute the environment and are more expensive long term than their reusable, sustainable counterparts. The PUMA x Modibodi collection is designed to be reused and replaces the need for disposable pads, liners and tampons, whilst ensuring women can stay extremely comfortable, odor free and protected from all leaks (not just periods). Modibodi’s proprietary Modifier Technology™ achieves this through its soft top layer, made of merino wool, which wicks moisture and sweat, a quick-drying absorbent microfibre middle layer, that locks away fluid and odor, and an additional waterproof protection in the bottom layer.

“No woman should have to sit on the sidelines of life because they have their period or bladder leaks,” said Kristy Chong, CEO and Founder, Modibodi. “We are thrilled to launch this collection with PUMA and together normalize menstruation and tackle the stigma that women can't be active on their periods or when experiencing any of life’s leaks.”

As part of the launch, PUMA and Modibodi will work with PUMA’s She Moves Us charity partner, Women Win, to donate a bundle pack of five briefs to 500 girls and women in need. This five-pack bundle covers a person for their monthly cycle and will last for up to four years to allow the person to confidently participate in sport and life without life’s leaks getting in the way.

The first PUMA x Modibodi active underwear collection will be available in May 2022 in selected stores and online at puma.com and modibodi.com.

*Observatory for Sport in Scotland (OSS) https://oss.scot/sport-participation-in-scotland-trends-and-future-prospects/

PUMA

PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 70 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 14,000 people worldwide, and is headquartered in Herzogenaurach/Germany.

MODIBODI

Founded in 2013, Modibodi® is Australia’s original leak-proof apparel brand, designing underwear, swimwear, active wear, maternity wear and reusable nappies to replace disposable hygiene products and offer a sustainable solution to manage periods, incontinence, discharge, breast milk leaks, sweat and more. Modibodi is warm, authentic and human. We help people with all kinds of leaky bodies get on with their lives. We’re plain speaking and taboo breaking. We’re comfortable in our own skin and not embarrassed to talk about leaky bodies – because they’re part of life. We offer a range of products and sizes across our three brands: Modibodi®, Modibodi RED for tweens and teens, and Modibodi Men to manage incontinence, sweat and chafing. Our Modibodi leak-proof products have been scientifically tested and proven to absorb fluid, resist odour, and keep you dry, thanks to the brand’s patented technology which keeps you feeling comfortable and confident and reduces the impact on the environment. Modibodi is committed to sustainability and social impact, helping end period poverty and normalising conversations about periods and leaks through education and supporting people in need globally. To date, Modibodi has sold millions of garments worldwide, saving billions of single-use disposable hygiene products such as pads, liners and tampons from ending up in landfill.

Changing the world should be as easy as changing your underwear. Waste-free, leak-free, worry-free protection.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PUMA
Gudrun Cämmerer
Teamhead Global PR
gudrun.caemmerer@puma.com
Phone +49 173 2199376

Modibodi
Lucy Lamming
PR & Partnerships Lead
lucylamming@modibodi.com
Phone +61 403 562 993

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye